Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Abiomed, Inc. FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial December 21, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD First Patients in the World Treated with Impella RP Flex with SmartAssist December 05, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year November 01, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure October 31, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare October 26, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson October 24, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure October 20, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath October 17, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support October 13, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification October 13, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77% September 20, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81% September 19, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients September 17, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC) September 16, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery September 13, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency* August 04, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification July 14, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps June 14, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference May 31, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year April 28, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification April 08, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD First Patient in Japan Treated with Impella 5.5 with SmartAssist April 06, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Abiomed to Host Investor Call on Impella ECP, the World’s Smallest Heart Pump at 9 French March 21, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference February 08, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year February 03, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification January 14, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology January 12, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study January 10, 2022 From Abiomed, Inc. Via Business Wire Tickers ABMD Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference December 29, 2021 From Abiomed, Inc. Via Business Wire Tickers ABMD Abiomed to Present at Upcoming Investor Conferences November 18, 2021 From Abiomed, Inc. Via Business Wire Tickers ABMD Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
